A concerning mortality signal makes routine antiviral prescribing harder to justify in critical illness.
Do not extrapolate an average 17-hour reduction in uncomplicated influenza symptoms to patients who require high-flow oxygen, ventilation or vasopressors.
An antiviral can have a plausible mechanism, appear in current guidance and still fail to improve survival. That is the problem raised by a recent preprint randomised trial of oseltamivir in patients with laboratory-confirmed influenza who were already critically ill.
The population matters. Participants were aged 12 years or older and required high-flow nasal oxygen, non-invasive or invasive ventilation, or vasopressor or inotrope support. This was not the uncomplicated influenza population from which the average 17-hour symptom reduction is drawn. In that setting, oseltamivir also increases nausea and vomiting. Neither finding answers the critical-care question.
The primary outcome was all-cause mortality at 90 days. Mortality was 14% with no antiviral, 20% after five days of oseltamivir and 19% after ten days. Neither course produced a survival benefit, and the Bayesian analysis generated high probabilities of harm and futility. That is enough to challenge automatic prescribing.
It is not enough to claim a precise causal increase in mortality. The trial was open label and part of an adaptive platform. Many sites did not offer the no-antiviral arm; the oseltamivir groups included patients with greater baseline illness severity; and important co-interventions after randomisation were not collected. Those limitations make the magnitude of any harmful effect uncertain.
Drug exposure was also untidy. Forty-two per cent of participants had received one oseltamivir dose before randomisation, 9% of controls received at least one dose afterwards, and treatment sometimes stopped at discharge. The intention-to-treat result therefore estimates assignment to an oseltamivir strategy rather than a clean comparison between complete treatment and no exposure. That limits what can be said about the drug’s direct effect, but it does not turn the absence of benefit into evidence of benefit.
The bedside problem is the conflict between emerging randomised evidence and guidance that still recommends oseltamivir for severe influenza. A preprint should not trigger an isolated, undocumented change by one clinician. It should interrupt the reflex prescription and prompt an explicit discussion with critical care, infectious diseases, pharmacy and the patient or substitute decision-maker.
For a patient with confirmed influenza who needs organ support, supportive care and investigation for bacterial co-infection remain central. The antiviral decision should be deliberate, multidisciplinary and recorded, with the mortality signal and the trial’s limitations both stated plainly.
New ST4 cardiology registrars are the main audience for BJCA Head Start, which combines practical role preparation, consultant-led subspecialty discussion, skills sessions and interactive cases. The podcast also announces fortnightly releases before weekly examination preparation resumes in spring 2027.
Foot drop localisation, hyperacusis in facial palsy and pain around the pectinate line turn anatomy into clinical decisions. The wider review also links renal filtration, intrinsic cardiac rhythm and neuronal energy use to organ homeostasis.
Communication under pressure is framed around context, evidence, limits of expertise and a few repeated messages. Prevention works better when movement, strength and connection are linked to patient-defined goals, while clinician wellbeing requires organisational action rather than resilience alone.
A randomised preprint in critically ill patients with confirmed influenza finds no 90-day survival benefit from five or ten days of oseltamivir and raises a possible harm signal. Site selection, baseline imbalance and treatment crossover limit certainty about its size.
Check whether a patient with confirmed influenza matches the trial population: high-flow nasal oxygen, ventilation or vasopressor or inotrope support. Pause automatic oseltamivir ordering and review expected benefit, possible harm, current guidance and patient preferences with critical care, infectious diseases and pharmacy. Document the reason for starting, continuing or withholding treatment.
An adult with laboratory-confirmed influenza requires invasive ventilation. A preprint randomised trial reports 90-day mortality of 14% without antiviral, 20% after five days of oseltamivir and 19% after ten days. Current guidance still recommends oseltamivir. What is the most appropriate treatment approach?
Pause automatic prescribing and review the expected benefit, possible harm, study limitations, current guidance and patient preferences with critical care, infectious diseases and pharmacy. Document the decision to start, continue or withhold treatment.
An adult develops foot drop after rapid weight loss and frequent leg crossing. Dorsiflexion and eversion are weak, but ankle inversion is preserved. Which lesion is most likely?
Common fibular neuropathy at the fibular neck. Preserved inversion favours a peripheral common fibular lesion over an L5 radiculopathy.
During a live interview, a presenter frames a healthcare intervention as ineffective even though the available evidence does not support that premise. How should the clinician respond?
Return to the established evidence, reframe the unsupported premise and repeat the intended clinical message without becoming adversarial.
.svg)